Qaly league tables: Handle with care

Citations

Cited by:

1. Victoria K. Brennan & Georgina Jones & Stephen Radley & Simon Dixon, 2021. "Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 747-756, September.
2. Pieter H. M. van Baal & Talitha L. Feenstra & Rudolf T. Hoogenveen & G. Ardine de Wit & Werner B. F. Brouwer, 2007. "Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost–utility ratio," Health Economics, John Wiley & Sons, Ltd., vol. 16(4), pages 421-433, April.
3. van Exel, Job & Baker, Rachel & Mason, Helen & Donaldson, Cam & Brouwer, Werner, 2015. "Public views on principles for health care priority setting: Findings of a European cross-country study using Q methodology," Social Science & Medicine, Elsevier, vol. 126(C), pages 128-137.
   • Job van Exel & Rachel Baker & Helen Mason & Cam Donaldson & Werner Brouwer, 2015. "Public views on principles for health care priority setting: Findings of a European cross-country study using Q methodology," Post-Print hal-01928069, HAL.
4. James Mason & Mike Drummond, 1995. "The DH register of cost-effectiveness studies: a review of study content and quality," Working Papers 128chedp, Centre for Health Economics, University of York.
5. Craig, Neil & Parkin, David & Gerard, Karen, 1995. "Clearing the fog on the Tyne: programme budgeting in Newcastle and North Tyneside Health Authority," Health Policy, Elsevier, vol. 33(2), pages 107-125, August.
6. Luke Vale & Cam Donaldson & Conal Daly & Marion Campbell & June Cody & Adrian Grant & Izhar Khan & Paul Lawrence & Shiela Wallace & Alison Macleod, 2000. "Evidence‐based medicine and health economics: a case study of end stage renal disease," Health Economics, John Wiley & Sons, Ltd., vol. 9(4), pages 337-351, June.
7. Lindholm, Lars & Hallgren, C. -G. & Boman, Kurt & Markgren, Kenth & Weinehall, Lars & Ogren, J. -E., 1999. "Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?," Health Policy, Elsevier, vol. 48(3), pages 155-170, August.
8. Baltussen, Rob & Ament, Andre & Leidl, Reiner, 1996. "Making cost assessments based on RCTs more useful to decision-makers," Health Policy, Elsevier, vol. 37(3), pages 163-183, September.
9. Virginia Wiseman & Craig Mitton & Mary M. Doyle‐Waters & Tom Drake & Lesong Conteh & Anthony T. Newall & Obinna Onwujekwe & Stephen Jan, 2016. "Using Economic Evidence to Set Healthcare Priorities in Low‐Income and Lower‐Middle‐Income Countries: A Systematic Review of Methodological Frameworks," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 140-161, February.
10. Marieke Krol & Jocé Papenburg & Marc Koopmanschap & Werner Brouwer, 2011. "Do Productivity Costs Matter?," PharmacoEconomics, Springer, vol. 29(7), pages 601-619, July.
11. Brouwer, W. B. F. & Koopmanschap, M. A. & Rutten, F. F. H., 1999. "Productivity losses without absence: measurement validation and empirical evidence," Health Policy, Elsevier, vol. 48(1), pages 13-27, July.
12. Don Husereau & Anthony Culyer & Peter Neumann & Philip Jacobs, 2015. "How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States?," Applied Health Economics and Health Policy, Springer, vol. 13(3), pages 273-279, June.
13. Lamiraud, Karine & von Bremen, Konrade & Donaldson, Cam, 2009. "The impact of information on patient preferences in different delivery patterns: A contingent valuation study of prescription versus OTC drugs," Health Policy, Elsevier, vol. 93(2-3), pages 102-110, December.
14. Nancy Thiry & Philippe Beutels & Pierre Damme & Eddy Doorslaer, 2003. "Economic Evaluations of Varicella Vaccination Programmes," PharmacoEconomics, Springer, vol. 21(1), pages 13-38, January.
15. John Cairns & Phil Shackley, 1993. "Sometimes sensitive, seldom specific: A review of the economics of screening," Health Economics, John Wiley & Sons, Ltd., vol. 2(1), pages 43-53, April.
16. Salkeld, Glenn & Davey, Peter & Arnolda, Gaston, 1995. "A critical review of health-related economic evaluations in Australia: implications for health policy," Health Policy, Elsevier, vol. 31(2), pages 111-125, February.
17. Tosin Lambe & Emma Frew & Natalie J. Ives & Rebecca L. Woolley & Carole Cummins & Elizabeth A. Brettell & Emma N. Barsoum & Nicholas J. A. Webb, 2018. "Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index–9 Dimension (CHU-9D) Score for Economic Evaluation in Children," PharmacoEconomics, Springer, vol. 36(4), pages 451-465, April.
18. Gerard, Karen & Smoker, Irenie & Seymour, Janelle, 1999. "Raising the quality of cost-utility analyses: lessons learnt and still to learn," Health Policy, Elsevier, vol. 46(3), pages 217-238, March.
19. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
20. Shackley, Phil & Cairns, John, 1996. "Evaluating the benefits of antenatal screening: an alternative approach," Health Policy, Elsevier, vol. 36(2), pages 103-115, May.
21. David K. Whynes & Aileen R. Neilson & Andrew R. Walker & Jack D. Hardcastle, 1998. "Faecal occult blood screening for colorectal cancer: is it cost‐effective?," Health Economics, John Wiley & Sons, Ltd., vol. 7(1), pages 21-29, February.
22. Marc A. Koopmanschap & Frans F. H. Rutten, 1994. "The impact of indirect costs on outcomes of health care programs," Health Economics, John Wiley & Sons, Ltd., vol. 3(6), pages 385-393, November.
23. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
24. Bernard Berg & Werner Brouwer & Marc Koopmanschap, 2004. "Economic valuation of informal care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(1), pages 36-45, February.
25. John Bridges, 2006. "Lean Systems Approaches to Health Technology Assessment," PharmacoEconomics, Springer, vol. 24(2), pages 101-109, December.
26. V. Srinivasan & David E. Bloom & Alex Khoury, 2022. "Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 371-381, May.
27. Calcott, Paul, 2000. "Health care evaluation, utilitarianism and distortionary taxes," Journal of Health Economics, Elsevier, vol. 19(5), pages 719-730, September.
28. Mikyung Kelly Seo & Mark Strong, 2021. "A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper," PharmacoEconomics, Springer, vol. 39(12), pages 1373-1381, December.